MA51570A - Polythérapies pour le traitement du carcinome hépatocellulaire - Google Patents

Polythérapies pour le traitement du carcinome hépatocellulaire

Info

Publication number
MA51570A
MA51570A MA051570A MA51570A MA51570A MA 51570 A MA51570 A MA 51570A MA 051570 A MA051570 A MA 051570A MA 51570 A MA51570 A MA 51570A MA 51570 A MA51570 A MA 51570A
Authority
MA
Morocco
Prior art keywords
polytherapies
treatment
hepatocellular carcinoma
hepatocellular
carcinoma
Prior art date
Application number
MA051570A
Other languages
English (en)
French (fr)
Inventor
Anand Selvaraj
Peter Smith
Original Assignee
Eisai R&D Man Co Ltd
Anand Selvaraj
Peter Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Anand Selvaraj, Peter Smith filed Critical Eisai R&D Man Co Ltd
Publication of MA51570A publication Critical patent/MA51570A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA051570A 2018-01-10 2019-01-09 Polythérapies pour le traitement du carcinome hépatocellulaire MA51570A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10

Publications (1)

Publication Number Publication Date
MA51570A true MA51570A (fr) 2020-11-18

Family

ID=65411938

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051570A MA51570A (fr) 2018-01-10 2019-01-09 Polythérapies pour le traitement du carcinome hépatocellulaire

Country Status (13)

Country Link
US (1) US11833119B2 (cg-RX-API-DMAC10.html)
EP (2) EP3737377B1 (cg-RX-API-DMAC10.html)
JP (2) JP7352569B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250073570A (cg-RX-API-DMAC10.html)
CN (1) CN111787922A (cg-RX-API-DMAC10.html)
AU (1) AU2019206480A1 (cg-RX-API-DMAC10.html)
BR (1) BR112020014112A2 (cg-RX-API-DMAC10.html)
CA (1) CA3088292A1 (cg-RX-API-DMAC10.html)
IL (1) IL275981A (cg-RX-API-DMAC10.html)
MA (1) MA51570A (cg-RX-API-DMAC10.html)
MX (1) MX2020007375A (cg-RX-API-DMAC10.html)
SG (1) SG11202006617RA (cg-RX-API-DMAC10.html)
WO (1) WO2019139977A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Fgfr4阻害剤の経口製剤によるがんの治療方法
KR20250003965A (ko) 2022-05-30 2025-01-07 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 암 치료용 약학적 조합 및 약학적 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
HUE025742T2 (hu) 2003-12-25 2016-04-28 Eisai R&D Man Co Ltd 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
CA2704000C (en) * 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2014009303A (es) * 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
CN105338977B (zh) * 2013-06-26 2018-10-16 卫材R&D管理有限公司 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
US10736900B2 (en) * 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US20160089365A1 (en) * 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN107304188A (zh) * 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用
JP7372740B2 (ja) * 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ

Also Published As

Publication number Publication date
IL275981A (en) 2020-08-31
RU2020126673A3 (cg-RX-API-DMAC10.html) 2022-04-19
CN111787922A (zh) 2020-10-16
RU2020126673A (ru) 2022-02-10
KR102811519B1 (ko) 2025-05-22
KR20200121302A (ko) 2020-10-23
JP7665700B2 (ja) 2025-04-21
JP2023175825A (ja) 2023-12-12
EP4667005A2 (en) 2025-12-24
EP3737377B1 (en) 2025-10-08
JP7352569B2 (ja) 2023-09-28
US11833119B2 (en) 2023-12-05
KR20250073570A (ko) 2025-05-27
JP2021512140A (ja) 2021-05-13
EP3737377A1 (en) 2020-11-18
SG11202006617RA (en) 2020-08-28
CA3088292A1 (en) 2019-07-18
AU2019206480A1 (en) 2020-08-27
MX2020007375A (es) 2020-11-09
EP4667005A3 (en) 2026-02-18
WO2019139977A1 (en) 2019-07-18
US20200360371A1 (en) 2020-11-19
BR112020014112A2 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
EP3431105A4 (en) MEDICAL COMPOSITION FOR THE TREATMENT OF CANCER
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA45539A (fr) Dihydropyranopyrimidines pour le traitement d'infections virales
EP3397963A4 (en) P38 MAPK INHIBITION FOR THE TREATMENT OF CANCER
EP3494142A4 (en) ANTI-SIGLEC-7 ANTIBODIES FOR TREATING CANCER
EP3452060A4 (en) COMBINATION THERAPY FOR CANCER TREATMENT
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3432927A4 (en) TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT
EP3400010A4 (en) ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS
EP3400011A4 (en) ANTI-CD20 COMBINATIONS FOR THE TREATMENT OF TUMORS
EP3541417A4 (en) COMBINATION IMMUNOTHERAPIES FOR TREATING CANCER
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
EP3490561A4 (en) COMBINATIONS FOR TREATING CANCER
EP3359255A4 (en) COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
EP3474854A4 (en) CANCER TREATMENT COMBINATIONS
EP3630196A4 (en) COMBINATION THERAPIES FOR TREATMENT OF CANCER
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3503887A4 (en) COMBINATIONS FOR TREATING CANCER
EP3443962A4 (en) Quinoline derivative for the treatment of gastric cancer
EP3630080A4 (en) USE OF EZH2 INHIBITORS TO TREAT CANCER
EP3773221A4 (en) TREATMENT OF HYDROCEPHALUS